Difference between revisions of "CD56"
Jump to navigation
Jump to search
m (myeloma) |
|||
| (9 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
'''CD56''' is a commonly available [[immunostain]] that is seen in a number of tumours. It is a sensitive marker of neuroendocrine differentiation. | '''CD56''' is a commonly available [[immunostain]] that is seen in a number of tumours. It is a sensitive [[neuroendocrine marker|marker of neuroendocrine differentiation]]. | ||
==Positive== | ==Positive== | ||
| Line 6: | Line 6: | ||
*[[Small cell carcinoma]]. | *[[Small cell carcinoma]]. | ||
*[[Merkel cell carcinoma]].<ref name=pmid12727026>{{Cite journal | last1 = Kurokawa | first1 = M. | last2 = Nabeshima | first2 = K. | last3 = Akiyama | first3 = Y. | last4 = Maeda | first4 = S. | last5 = Nishida | first5 = T. | last6 = Nakayama | first6 = F. | last7 = Amano | first7 = M. | last8 = Ogata | first8 = K. | last9 = Setoyama | first9 = M. | title = CD56: a useful marker for diagnosing Merkel cell carcinoma. | journal = J Dermatol Sci | volume = 31 | issue = 3 | pages = 219-24 | month = May | year = 2003 | doi = | PMID = 12727026 }}</ref> | *[[Merkel cell carcinoma]].<ref name=pmid12727026>{{Cite journal | last1 = Kurokawa | first1 = M. | last2 = Nabeshima | first2 = K. | last3 = Akiyama | first3 = Y. | last4 = Maeda | first4 = S. | last5 = Nishida | first5 = T. | last6 = Nakayama | first6 = F. | last7 = Amano | first7 = M. | last8 = Ogata | first8 = K. | last9 = Setoyama | first9 = M. | title = CD56: a useful marker for diagnosing Merkel cell carcinoma. | journal = J Dermatol Sci | volume = 31 | issue = 3 | pages = 219-24 | month = May | year = 2003 | doi = | PMID = 12727026 }}</ref> | ||
===Lymphoid=== | |||
*[[Acute myeloid leukemia]].<ref name=nordiqc>URL: [http://www.nordiqc.org/Epitopes/CD56/CD56.htm http://www.nordiqc.org/Epitopes/CD56/CD56.htm]. Accessed on: September 13, 2014.</ref> | |||
*[[Chronic myeloid leukemia]].<ref name=nordiqc/> | |||
*[[Extranodal NK/T-cell lymphoma, nasal type]]. | |||
*[[Hepatosplenic T-cell lymphoma]]. | |||
*[[Plasma cell myeloma]] | |||
===Others=== | ===Others=== | ||
*[[Rhabdomyosarcoma]].<ref name=pmid18487991>{{Cite journal | last1 = Bahrami | first1 = A. | last2 = Gown | first2 = AM. | last3 = Baird | first3 = GS. | last4 = Hicks | first4 = MJ. | last5 = Folpe | first5 = AL. | title = Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. | journal = Mod Pathol | volume = 21 | issue = 7 | pages = 795-806 | month = Jul | year = 2008 | doi = 10.1038/modpathol.2008.86 | PMID = 18487991 }}</ref> | |||
*[[Solid pseudopapillary tumour]]. | |||
*[[Follicular dendritic cell sarcoma]]. | *[[Follicular dendritic cell sarcoma]]. | ||
*[[ | |||
==Occasionally positive== | |||
*[[Renal cell carcinoma]] ~18% of cases.<ref name=pmid20462442>{{cite journal |authors=Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P |title=Evaluation of neuroendocrine markers in renal cell carcinoma |journal=Diagn Pathol |volume=5 |issue= |pages=28 |date=May 2010 |pmid=20462442 |pmc=2876076 |doi=10.1186/1746-1596-5-28 |url=}}</ref> | |||
==See also== | ==See also== | ||
*[[Immunohistochemistry]]. | *[[Immunohistochemistry]]. | ||
Latest revision as of 22:39, 26 March 2021
CD56 is a commonly available immunostain that is seen in a number of tumours. It is a sensitive marker of neuroendocrine differentiation.
Positive
Carcinomas
Lymphoid
- Acute myeloid leukemia.[2]
- Chronic myeloid leukemia.[2]
- Extranodal NK/T-cell lymphoma, nasal type.
- Hepatosplenic T-cell lymphoma.
- Plasma cell myeloma
Others
Occasionally positive
- Renal cell carcinoma ~18% of cases.[4]
See also
References
- ↑ Kurokawa, M.; Nabeshima, K.; Akiyama, Y.; Maeda, S.; Nishida, T.; Nakayama, F.; Amano, M.; Ogata, K. et al. (May 2003). "CD56: a useful marker for diagnosing Merkel cell carcinoma.". J Dermatol Sci 31 (3): 219-24. PMID 12727026.
- ↑ 2.0 2.1 URL: http://www.nordiqc.org/Epitopes/CD56/CD56.htm. Accessed on: September 13, 2014.
- ↑ Bahrami, A.; Gown, AM.; Baird, GS.; Hicks, MJ.; Folpe, AL. (Jul 2008). "Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.". Mod Pathol 21 (7): 795-806. doi:10.1038/modpathol.2008.86. PMID 18487991.
- ↑ Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P (May 2010). "Evaluation of neuroendocrine markers in renal cell carcinoma". Diagn Pathol 5: 28. doi:10.1186/1746-1596-5-28. PMC 2876076. PMID 20462442. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876076/.